Tadalafil tablets recalled for manufacturing quality control deviations
Accord Healthcare is recalling Tadalafil 10 mg tablets in the United States, Puerto Rico, and Canada due to manufacturing quality control deviations discovered during an FDA inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall based on manufacturing quality control deviations discovered during inspection. No adverse events have been reported, but CGMP deviations represent potential risk to product integrity in a prescription medication.
Plain-English summary
Accord Healthcare, Inc., is recalling Tadalafil tablets, 10 mg strength, in both 30-count and 500-count bottles. The recall affects approximately 176,323 bottles distributed throughout the United States, Puerto Rico, and Canada.
The recall was initiated following an FDA inspection that identified Current Good Manufacturing Practice (CGMP) deviations in the manufacturing process. This is classified as a Class II recall.
Consumers should not discard their medication without consulting their healthcare provider. Affected lot numbers and expiration dates are available in the full FDA recall notice. Consumers with questions should contact their healthcare provider or pharmacist for guidance on obtaining replacement medication.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Oral Tablet
- Hazard
- Affected units
- 176,323
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2002525
- Exp. Date 4/30/2023
- P2004442
- Exp. Date 7/31/2023
- P2005014
- Exp. Date 8/31/2023
- P2005015
- P2005016
- P2005825
- Exp. Date 10/31/2023
- P2005824
- P2005826
- P2100368
- Exp. Date 12/31/2023
- P2100444
- P2101262
- Exp. Date 2/29/2024
- P2101263
- P2200813
- Exp. Date 1/31/2025
UPCs (5)
- 0316729372107
- 0316729369107
- 0316729370103
- 316729371100
- 316729371162
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · TADALAFIL
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- ModerateTadalafil tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Accord Healthcare, Inc.
See all →- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29